AzTrials
AzTrials

Post-prandial Glycaemic ResponsePEA3NCT03306706

Effect of Peas in Muffins on Blood Glucose and Appetite Control

A study testing Whole pea muffins, Split pea muffins and Wheat muffins in people with Post-prandial Glycaemic Response and Satiety, run by St. Boniface Hospital at 1 site in Canada.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This study is part of a group of studies whose overall goal is to accurately define the physiochemical and structural effects of pea varieties and relate these to blood glucose attenuation and appetite related sensations in healthy human volunteers. Read more about this study

Who is it for?
Ages 18 to 40 yearsHealthy volunteers can take part
Conditions the study is for
Post-prandial Glycaemic Response, Satiety
What is being tested?
Whole pea muffins, Split pea muffins and Wheat muffins
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
24 participants
Where
1 siteCanada
Study dates
7 Nov 2017to Jan 2025
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Generally healthy male or female, between the age of 18-40 years;
  • Body mass index (BMI) 18.5-30.0 kg/m2;
  • Habitually consume breakfast, lunch and dinner in the morning, mid-day and evening, respectively.
  • Willing to provide informed consent;
  • Willing/able to comply with the requirements of the study.

Who cannot join

  • Pregnant or lactating;
  • Medical history of diabetes mellitus, fasting blood glucose ≥6.1 mmol/L, HbA1c ≥6.0%, or use of insulin or oral medication to control blood sugar;
  • Medical history of cardiovascular disease;
  • Systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg;
  • Fasting plasma total cholesterol >7.8 mmol/L;
  • Fasting plasma HDL <0.9 mmol/L;
Show all 25Show fewer
  • Fasting plasma LDL >5.0 mmol/L;
  • Fasting plasma triglycerides >2.3 mmol/L;
  • Major surgery within the last 3 months;
  • Medical history of inflammatory disease (ie. Systemic lupus erythematosis, rheumatoid arthritis, psoriasis) or use of any corticosteroid medications within 3 months;
  • Medical history of liver disease or liver dysfunction (defined as plasma AST or ALT ≥1.5 times the upper limit of normal (ULN));
  • Medical history of kidney disease or kidney dysfunction (defined as blood urea nitrogen and creatinine ≥ 1.8 times the ULN));
  • Presence of a gastrointestinal disorder, daily use of any stomach acid-lowering medications or laxatives (including fibre supplements) within the past month or antibiotic use within the past 6 weeks;
  • Active treatment for any type of cancer within 1 year prior to study start;
  • Shift worker (a system of employment where an individual's normal hours of work are in part, outside the period of normal working day; 6am and 8pm);
  • Smoking, use of tobacco or a nicotine replacement product (within the last 3 months);
  • Allergies to peas;
  • Aversion or unwillingness to eat study foods;
  • Consuming >4 servings of pulses per week;
  • Use of any prescription or non-prescription drug, herbal or nutritional supplement known to affect glycaemia or appetite;
  • Participation in another clinical trial, current or in the past 4 weeks;
  • Unstable body weight (defined as >5% change in 3 months) or actively participating in a weight loss program.
  • Physical Activity Level >1.8.
  • Restraint score >13 (factor 1) on the Three Factor Eating Questionnaire.
  • Other medical, psychiatric, or behavioral factors that in the judgment of the principal Investigator may interfere with study participation or the ability to follow the intervention protocol;

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • I.H. Asper Clinical Research Institute

    Winnipeg, Manitoba, R2H2A6

Other trials in Canada

About this study

Official title: A Randomized, Controlled, Cross-over Trial Examining the Effect of Peas in Muffins on Post-prandial Glycaemic Response and Satiety in Healthy Adults.

This study is part of a group of studies whose overall goal is to accurately define the physiochemical and structural effects of pea varieties and relate these to blood glucose attenuation and appetite related sensations in healthy human volunteers.

Read the detailed description

A randomized, controlled, cross-over study designed to examine the postprandial glycaemic response and appetite related sensations to peas in muffins will be conducted at the I.H. Asper Clinical Research Institute in Winnipeg, Manitoba. Eligible participants who have provided consent will be asked to attend 4 clinic visits in a fasted state. Participants will be given muffins containing peas at 2 visits and muffins without peas at 2 visits. At each visit participants will provide 7 venous blood samples via indwelling catheter, 7 capillary blood samples via finger poke, 2 urine samples, 5 questionnaires about their appetite and a questionnaire about the acceptability of the products. At the end of each visit, participants will eat pizza ad libitum, and the amount of pizza consumed will be measured to determine if the peas influenced the amount of calories consumed at lunch. Participants will record their food/beverage intake for the rest of the day. Each visit will last approximately 3h and be separated by 3-14 days.

Being tested
Whole pea muffins, Split pea muffins, Wheat muffins
Keywords
blood sugar, insulin, appetite, peas
Medical subject headings
Insulin Resistance

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Whole pea muffinsDietary supplement

    2 muffins containing whole peas

  • Split pea muffinsDietary supplement

    2 muffins containing split peas

  • Wheat muffinsDietary supplement

    2 muffins containing wheat

Study groups in NCT03306706
Study groupRoleWhat they receive
whole yellow peaExperimental2 muffins containing 25g available carbohydrate from whole yellow peas. Intervention: Whole pea muffins
Receives: Dietary Supplement: Whole pea muffins
split yellow peaExperimental2 muffins containing 25g available carbohydrate from split yellow peas. Intervention: Split pea muffins
Receives: Dietary Supplement: Split pea muffins
wheat-PPGRPlacebo comparator2 muffins containing 25g available carbohydrate from wheat flour. Intervention: Wheat muffins
Receives: Dietary Supplement: Wheat muffins
wheat-satietyPlacebo comparator2 muffins containing wheat flour to match the calories in the whole and split pea muffins. Intervention: Wheat muffins
Receives: Dietary Supplement: Wheat muffins

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Post-prandial glucose response

    iAUC glucose

    Measured: 120 min

  2. Post-prandial insulin

    iAUC insulin

    Measured: 120 min

Secondary outcomes (1)
  1. Appetite ratings

    AUC for hunger, fullness, desire to eat and prospective consumption using visual analog scales

    Measured: 120 min

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Oct 2017
  2. Study start7 Nov 2017
  3. Primary completion21 Feb 2019
  4. Study completionJan 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Crossover
Model description
randomized, controlled, cross-over
Masking
None (open label)
Enrolment
24 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03306706
Sponsor's protocol ID
RRC/2017/1702
Other IDs
HS21108 (B2017:106)
Acronym
PEA3
Status last verified
Nov 2024
First submitted
2 Oct 2017
Last updated
29 Nov 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: All IPD that underlie results in a publication.

Publications

  • Public Health Agency of Canada and the Canadian Institute for Health Information. Obesity in Canada: A joint report from the Public Health Agency of Canada and the Canadian institute for health information. Government of Canada; 2011.

  • Public Health Authority of Canada. Diabetes in Canada: Facts and figures from a public health perspective. 2011

  • Sievenpiper JL, Kendall CW, Esfahani A, Wong JM, Carleton AJ, Jiang HY, Bazinet RP, Vidgen E, Jenkins DJ. Effect of non-oil-seed pulses on glycaemic control: a systematic review and meta-analysis of randomised controlled experimental trials in people with and without diabetes. Diabetologia. 2009 Aug;52(8):1479-95. doi: 10.1007/s00125-009-1395-7. Epub 2009 Jun 13.

    PubMed 19526214
  • Hamberg O, Rumessen JJ, Gudmand-Hoyer E. Blood glucose response to pea fiber: comparisons with sugar beet fiber and wheat bran. Am J Clin Nutr. 1989 Aug;50(2):324-8. doi: 10.1093/ajcn/50.2.324.

    PubMed 2547300
  • Marinangeli CP, Jones PJ. Chronic intake of fractionated yellow pea flour reduces postprandial energy expenditure and carbohydrate oxidation. J Med Food. 2011 Dec;14(12):1654-62. doi: 10.1089/jmf.2010.0255.

    PubMed 22145774
  • Smith CE, Mollard RC, Luhovyy BL, Anderson GH. The effect of yellow pea protein and fibre on short-term food intake, subjective appetite and glycaemic response in healthy young men. Br J Nutr. 2012 Aug;108 Suppl 1:S74-80. doi: 10.1017/S0007114512000700.

    PubMed 22916818
  • Jenkins DJ, Thorne MJ, Camelon K, Jenkins A, Rao AV, Taylor RH, Thompson LU, Kalmusky J, Reichert R, Francis T. Effect of processing on digestibility and the blood glucose response: a study of lentils. Am J Clin Nutr. 1982 Dec;36(6):1093-101. doi: 10.1093/ajcn/36.6.1093.

    PubMed 6293296
  • Li H, Song F, Xing J, Tsao R, Liu Z, Liu S. Screening and structural characterization of alpha-glucosidase inhibitors from hawthorn leaf flavonoids extract by ultrafiltration LC-DAD-MS(n) and SORI-CID FTICR MS. J Am Soc Mass Spectrom. 2009 Aug;20(8):1496-503. doi: 10.1016/j.jasms.2009.04.003. Epub 2009 Apr 14.

    PubMed 19443236
  • Habtemariam S. A-glucosidase inhibitory activity of kaempferol-3-O-rutinoside. Nat Prod Commun. 2011 Feb;6(2):201-3.

    PubMed 21425674
  • Blundell J, de Graaf C, Hulshof T, Jebb S, Livingstone B, Lluch A, Mela D, Salah S, Schuring E, van der Knaap H, Westerterp M. Appetite control: methodological aspects of the evaluation of foods. Obes Rev. 2010 Mar;11(3):251-70. doi: 10.1111/j.1467-789X.2010.00714.x. Epub 2010 Jan 29.

    PubMed 20122136
  • EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Guidance on the scientific requirements for health claims related to appetite ratings, weight management, and blood glucose concentrations. EFSA J. 2012 Mar 21;10(3):2604. doi: 10.2903/j.efsa.2012.2604. eCollection 2012 Mar. No abstract available.

    PubMed 42112026
  • Health Canada. Draft guidance document: Satiety health claims on food [Internet].; 2012. Available from: http://www.hc-sc.gc.ca/fn-an/consult/satiety-satiete/document-consultation-eng.php

  • Ames N, Blewett H, Storsley J, Thandapilly SJ, Zahradka P, Taylor C. A double-blind randomised controlled trial testing the effect of a barley product containing varying amounts and types of fibre on the postprandial glucose response of healthy volunteers. Br J Nutr. 2015 May 14;113(9):1373-83. doi: 10.1017/S0007114515000367. Epub 2015 Apr 8.

    PubMed 25850814
  • Johansson G, Westerterp KR. Assessment of the physical activity level with two questions: validation with doubly labeled water. Int J Obes (Lond). 2008 Jun;32(6):1031-3. doi: 10.1038/ijo.2008.42. Epub 2008 Apr 8.

    PubMed 18392036
  • Rabiee A, Magruder JT, Grant C, Salas-Carrillo R, Gillette A, DuBois J, Shannon RP, Andersen DK, Elahi D. Accuracy and reliability of the Nova StatStrip(R) glucose meter for real-time blood glucose determinations during glucose clamp studies. J Diabetes Sci Technol. 2010 Sep 1;4(5):1195-201. doi: 10.1177/193229681000400519.

    PubMed 20920440

Questions about this trial

What is this clinical trial studying?

A study testing Whole pea muffins, Split pea muffins and Wheat muffins in people with Post-prandial Glycaemic Response and Satiety, run by St. Boniface Hospital at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 29 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Post-prandial glucose response (time frame: 120 min). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03306706, which also lists 17 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Nov 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in